Predictors of patient and graft survival following liver transplantation for hepatitis C

Michael Charlton, Eric Seaberg, Russell Wiesner, James Everhart, Rowen K Zetterman, John Lake, Katherine Detre, Jay Hoofnagle

Research output: Contribution to journalArticle

493 Citations (Scopus)

Abstract

End-stage liver disease secondary to hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the United States. Recurrence of HCV infection is nearly universal. We studied the patients enrolled in the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database to determine whether pretransplantation patient or donor variables could identify a subset of HCV- infected recipients with poor patient survival. Between April 15, 1990, and June 30, 1994, 166 HCV-infected and 509 HCV-negative patients underwent liver transplantation at the participating institutions. Median follow-up was 5.0 years for HCV-infected and 5.2 years for HCV-negative recipients. Pretransplantation donor and recipient characteristics, and patient and graft survival, were prospectively collected and compared. Cumulative patient survival for HCV-infected recipients was similar to that of recipients transplanted for chronic nonB-C hepatitis, or alcoholic and metabolic liver disease, better than that of patients transplanted for malignancy or hepatitis B (P = .02 and P = .003, respectively), and significantly worse than that of patients transplanted for cholestatic liver disease (P = .001). Recipients who had a pretransplantation HCV-RNA titer of ≤ 1 x 106 vEq/mL had a cumulative 5-year survival of 57% versus 84% for those with HCV-RNA titers of <1 x 106 vEq/mL (P = .0001). Patient and graft survival did not vary with recipient gender, HCV genotype, or induction immunosuppression regimen among the HCV-infected recipients. While long-term patient and graft survival following liver transplantation for end-stage liver disease secondary to HCV are generally comparable with that of most other indications, higher pretransplantation HCV-RNA titers are strongly associated with poor survival among HCV-infected recipients.

Original languageEnglish (US)
Pages (from-to)823-830
Number of pages8
JournalHepatology
Volume28
Issue number3
DOIs
StatePublished - Jan 1 1998

Fingerprint

Graft Survival
Hepatitis C
Hepacivirus
Liver Transplantation
Viral Load
End Stage Liver Disease
Survival
Virus Diseases
RNA
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Tissue Donors
Alcoholic Liver Diseases
Metabolic Diseases
Chronic Hepatitis C
Hepatitis B
Immunosuppression
Liver Diseases

ASJC Scopus subject areas

  • Hepatology

Cite this

Charlton, M., Seaberg, E., Wiesner, R., Everhart, J., Zetterman, R. K., Lake, J., ... Hoofnagle, J. (1998). Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology, 28(3), 823-830. https://doi.org/10.1002/hep.510280333

Predictors of patient and graft survival following liver transplantation for hepatitis C. / Charlton, Michael; Seaberg, Eric; Wiesner, Russell; Everhart, James; Zetterman, Rowen K; Lake, John; Detre, Katherine; Hoofnagle, Jay.

In: Hepatology, Vol. 28, No. 3, 01.01.1998, p. 823-830.

Research output: Contribution to journalArticle

Charlton, M, Seaberg, E, Wiesner, R, Everhart, J, Zetterman, RK, Lake, J, Detre, K & Hoofnagle, J 1998, 'Predictors of patient and graft survival following liver transplantation for hepatitis C', Hepatology, vol. 28, no. 3, pp. 823-830. https://doi.org/10.1002/hep.510280333
Charlton, Michael ; Seaberg, Eric ; Wiesner, Russell ; Everhart, James ; Zetterman, Rowen K ; Lake, John ; Detre, Katherine ; Hoofnagle, Jay. / Predictors of patient and graft survival following liver transplantation for hepatitis C. In: Hepatology. 1998 ; Vol. 28, No. 3. pp. 823-830.
@article{e3bd00bfd47a4e88bb3cc767b8ceeb9d,
title = "Predictors of patient and graft survival following liver transplantation for hepatitis C",
abstract = "End-stage liver disease secondary to hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the United States. Recurrence of HCV infection is nearly universal. We studied the patients enrolled in the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database to determine whether pretransplantation patient or donor variables could identify a subset of HCV- infected recipients with poor patient survival. Between April 15, 1990, and June 30, 1994, 166 HCV-infected and 509 HCV-negative patients underwent liver transplantation at the participating institutions. Median follow-up was 5.0 years for HCV-infected and 5.2 years for HCV-negative recipients. Pretransplantation donor and recipient characteristics, and patient and graft survival, were prospectively collected and compared. Cumulative patient survival for HCV-infected recipients was similar to that of recipients transplanted for chronic nonB-C hepatitis, or alcoholic and metabolic liver disease, better than that of patients transplanted for malignancy or hepatitis B (P = .02 and P = .003, respectively), and significantly worse than that of patients transplanted for cholestatic liver disease (P = .001). Recipients who had a pretransplantation HCV-RNA titer of ≤ 1 x 106 vEq/mL had a cumulative 5-year survival of 57{\%} versus 84{\%} for those with HCV-RNA titers of <1 x 106 vEq/mL (P = .0001). Patient and graft survival did not vary with recipient gender, HCV genotype, or induction immunosuppression regimen among the HCV-infected recipients. While long-term patient and graft survival following liver transplantation for end-stage liver disease secondary to HCV are generally comparable with that of most other indications, higher pretransplantation HCV-RNA titers are strongly associated with poor survival among HCV-infected recipients.",
author = "Michael Charlton and Eric Seaberg and Russell Wiesner and James Everhart and Zetterman, {Rowen K} and John Lake and Katherine Detre and Jay Hoofnagle",
year = "1998",
month = "1",
day = "1",
doi = "10.1002/hep.510280333",
language = "English (US)",
volume = "28",
pages = "823--830",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Predictors of patient and graft survival following liver transplantation for hepatitis C

AU - Charlton, Michael

AU - Seaberg, Eric

AU - Wiesner, Russell

AU - Everhart, James

AU - Zetterman, Rowen K

AU - Lake, John

AU - Detre, Katherine

AU - Hoofnagle, Jay

PY - 1998/1/1

Y1 - 1998/1/1

N2 - End-stage liver disease secondary to hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the United States. Recurrence of HCV infection is nearly universal. We studied the patients enrolled in the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database to determine whether pretransplantation patient or donor variables could identify a subset of HCV- infected recipients with poor patient survival. Between April 15, 1990, and June 30, 1994, 166 HCV-infected and 509 HCV-negative patients underwent liver transplantation at the participating institutions. Median follow-up was 5.0 years for HCV-infected and 5.2 years for HCV-negative recipients. Pretransplantation donor and recipient characteristics, and patient and graft survival, were prospectively collected and compared. Cumulative patient survival for HCV-infected recipients was similar to that of recipients transplanted for chronic nonB-C hepatitis, or alcoholic and metabolic liver disease, better than that of patients transplanted for malignancy or hepatitis B (P = .02 and P = .003, respectively), and significantly worse than that of patients transplanted for cholestatic liver disease (P = .001). Recipients who had a pretransplantation HCV-RNA titer of ≤ 1 x 106 vEq/mL had a cumulative 5-year survival of 57% versus 84% for those with HCV-RNA titers of <1 x 106 vEq/mL (P = .0001). Patient and graft survival did not vary with recipient gender, HCV genotype, or induction immunosuppression regimen among the HCV-infected recipients. While long-term patient and graft survival following liver transplantation for end-stage liver disease secondary to HCV are generally comparable with that of most other indications, higher pretransplantation HCV-RNA titers are strongly associated with poor survival among HCV-infected recipients.

AB - End-stage liver disease secondary to hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the United States. Recurrence of HCV infection is nearly universal. We studied the patients enrolled in the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database to determine whether pretransplantation patient or donor variables could identify a subset of HCV- infected recipients with poor patient survival. Between April 15, 1990, and June 30, 1994, 166 HCV-infected and 509 HCV-negative patients underwent liver transplantation at the participating institutions. Median follow-up was 5.0 years for HCV-infected and 5.2 years for HCV-negative recipients. Pretransplantation donor and recipient characteristics, and patient and graft survival, were prospectively collected and compared. Cumulative patient survival for HCV-infected recipients was similar to that of recipients transplanted for chronic nonB-C hepatitis, or alcoholic and metabolic liver disease, better than that of patients transplanted for malignancy or hepatitis B (P = .02 and P = .003, respectively), and significantly worse than that of patients transplanted for cholestatic liver disease (P = .001). Recipients who had a pretransplantation HCV-RNA titer of ≤ 1 x 106 vEq/mL had a cumulative 5-year survival of 57% versus 84% for those with HCV-RNA titers of <1 x 106 vEq/mL (P = .0001). Patient and graft survival did not vary with recipient gender, HCV genotype, or induction immunosuppression regimen among the HCV-infected recipients. While long-term patient and graft survival following liver transplantation for end-stage liver disease secondary to HCV are generally comparable with that of most other indications, higher pretransplantation HCV-RNA titers are strongly associated with poor survival among HCV-infected recipients.

UR - http://www.scopus.com/inward/record.url?scp=0031783001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031783001&partnerID=8YFLogxK

U2 - 10.1002/hep.510280333

DO - 10.1002/hep.510280333

M3 - Article

VL - 28

SP - 823

EP - 830

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -